ACCURAY INC: insider trades · United States · SEC (Form 4)

About ACCURAY INC

Accuray Incorporated (ticker: ARAY) is a U.S.-based medical technology company listed on NASDAQ in the United States, focused on precision radiation therapy systems for cancer treatment and neurosurgical radiosurgery. Headquartered in Madison, Wisconsin, Accuray positions itself as a differentiated provider of advanced radiation oncology solutions for hospitals and treatment centers seeking highly targeted delivery for complex cases while also making standard workflows easier to manage. For equity investors, that places the company squarely in the healthcare equipment sub-sector, with exposure to clinical adoption cycles, capital purchasing decisions by providers, and the regulatory environment that governs medical devices. ([accuray.com](https://www.accuray.com/company/)) Founded in 1990, Accuray built its business around two flagship platforms, CyberKnife and TomoTherapy, and has since expanded its portfolio with Radixact, Accuray Precision treatment planning software, and iDMS data management tools. The company designs, manufactures, sells, and services radiation therapy systems and related software, creating a business model that combines higher-value system placements with recurring service revenue tied to the installed base. That mix is strategically important because it can help balance the lumpiness of system orders with more stable service economics over time. ([accuray.com](https://www.accuray.com/company/)) Competitive positioning is centered on precision, automation, and clinical versatility. Accuray markets its technology for oncology and neuro-radiosurgery applications and emphasizes its ability to treat difficult-to-address tumors with accuracy. The company’s global footprint is also a defining feature: manufacturing facilities are located in Madison, Wisconsin and Chengdu, China, with regional offices in Switzerland, Japan, China, and Hong Kong. This international presence supports commercialization, but it also introduces meaningful exposure to supply chain disruption, tariffs, foreign exchange volatility, and other cross-border operating risks. ([accuray.com](https://www.accuray.com/company/)) Recent developments matter for the investment case. In August 2025, Accuray reported fiscal fourth-quarter and full-year 2025 results, highlighted service revenue growth, completed debt refinancing, and issued fiscal 2026 guidance. Management guided to total net revenue of $471 million to $485 million and adjusted EBITDA of $31 million to $35 million. The company also pointed to continued progress in customer adoption, product portfolio expansion, and its China joint venture. For investors tracking SEC Form 4 insider activity, the name sits in a small-cap healthcare technology profile where operational execution, balance-sheet management, and international commercialization are all key swing factors. ([investors.accuray.com](https://investors.accuray.com/news-releases/news-release-details/accuray-reports-fourth-quarter-and-fiscal-2025-financial-results))